Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT05953480 is Phase 2b, active not recruiting, enrollment completed Dec 2025 per StemRIM/Shionogi update. Primary completion estimated Mar 2026. No public readout available as of Apr 2026. Prior Japan Phase 2 positive but distinct trial.
Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT05953480 is active not recruiting with estimated primary completion Mar 2026. Enrollment completed Dec 2025. No public topline results, readout, or efficacy interpretation available as of Apr 2026. Prior Japanese Ph2 positive but distinct trial. Interim futility analysis continued high dose, but not final readout.
Found Apr 6, 2026, 2:41 PMReviewed Apr 6, 2026, 2:42 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout was found. Sponsor/partner materials in Dec 2025 and Mar 2026 still describe NCT05953480 as ongoing, with enrollment just completed and top-line results listed as a future milestone. Without a public readout, the Phase 2 outcome cannot be classified positive or negative.
Found Apr 3, 2026, 4:31 PMReviewed Apr 3, 2026, 4:46 PM
Sponsorstemrim.comDec 25, 2025, 12:00 AM
StemRIM Announces Completion of Patient Enrollment in the Global Phase 2b Clinical Trial of the Redasemtide for Acute Ischemic Stroke
Partner update says patient enrollment in the global Phase 2b trial was completed on Dec. 25, 2025; primary endpoint is mRS at 90 days, indicating results were not yet available then.
Sponsorfs2.magicalir.netMar 13, 2026, 12:00 AM
Presentation Material: Financial Results for the Six Months Ended January 31, 2026
March 13, 2026 investor deck lists REvive Phase 2b as 'Last Patient In' and names 'announcement of top-line results' as an upcoming milestone, so no public topline readout had occurred yet.
Sponsorshionogi.com
Shionogi Clinical Trials in the U.S.
Shionogi's 2026 clinical-trials page still describes REvive (NCT05953480) as a Phase 2b study evaluating redasemtide in acute ischemic stroke, not as a study with reported results.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public efficacy readout found for this exact Phase 2b trial. The latest sponsor update says enrollment completed on 2025-12-25 and the study was still progressing as planned; an external tracker using ClinicalTrials.gov data still listed the trial as ongoing with no results reported as of 2026-03-11.
Found Apr 1, 2026, 8:21 PMReviewed Apr 1, 2026, 8:22 PM